CAS 210421-74-2|Sitaxentan sodium
| Common Name | Sitaxentan sodium | ||
|---|---|---|---|
| CAS Number | 210421-74-2 | Molecular Weight | 476.88600 |
| Density | / | Boiling Point | / |
| Molecular Formula | C18H14ClN2NaO6S2 | Melting Point | / |
| MSDS | USA | Flash Point | / |
Names
| Name | sodium,(4-chloro-3-methyl-1,2-oxazol-5-yl)-[2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophen-3-yl]sulfonylazanide |
|---|---|
| Synonym | More Synonyms |
Sitaxentan sodium BiologicalActivity
| Description | Sitaxsentan (sodium) is an orally active, highly selective antagonist of endothelin A receptors. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Endothelin ReceptorResearch Areas >>Cardiovascular Disease |
| In Vitro | Sitaxsentan and Bosentan attenuate NTCP transport at higher concentrations, and inhibit human hepatic transporters, which provides a potential mechanism for the increased hepatotoxicity observed for these agents in the clinical setting. Only sitaxsentan decreased OATP transport (52%)[1]. Sitaxsentan and sitaxsentan combined with sildenafil completely prevent the increased expressions of endothelin-1 and of the ETB receptor. Sitaxsentan alone partially restores the expressions of BMPR-1A and BMPR-2. The combination of sildenafil and sitaxsentan further restores the expressions of BMPR-1A and BMPR-2, which remaines, however, decreased compared with controls[3]. |
| In Vivo | Sitaxsentan (5 mg/kg infused iv 10 min prior to onset of hypoxia) completely blocks hypoxia-induced vasoconstriction and this group does not differ from air controls. Oral administration of sitaxsentan, significantly attenuates the increase in MPAP, while the administration of sitaxsentan to rats exposed to normal oxygen levels is without effect on MPAP[2]. Sitaxsentan alone limits shunt-induced increase in MT. Sitaxsentan combined with sildenafil more effectively prevents this remodeling, which, however, tends to remain increased compared with controls[3]. |
| Animal Admin | After an initial 2-week period of hypoxic exposure (10% O2) sitaxsentan (15 or 30 mg/kg body weight per day in the drinking water) is administered for 4 weeks during continuous exposure to hypoxia. At the conclusion of the 4 week period of hypoxia, femoral and pulmonary arterial cannulation and measurement of MPAP, MSAP, and HR are performed. |
| References | [1]. Hartman JC, et al. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol. 2010 Jun;88 [2]. Tilton RG, et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Pulm Pharmacol Ther. 2000;13(2):87-97. [3]. Rondelet B, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1118-23. Epub 2010 Aug 6. |
Chemical & Physical Properties
| Molecular Formula | C18H14ClN2NaO6S2 |
|---|---|
| Molecular Weight | 476.88600 |
| Exact Mass | 475.98800 |
| PSA | 135.56000 |
| LogP | 4.90080 |
| Appearance of Characters | white to beige |
| InChIKey | MDTNUYUCUYPIHE-UHFFFAOYSA-N |
| SMILES | Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)[N-]c1onc(C)c1Cl)OCO2.[Na+] |
| Storage condition | room temp |
| Water Solubility | H2O: soluble10mg/mL (clear solution) |
Safety Information
| RIDADR | NONH for all modes of transport |
|---|---|
| RTECS | XN0296600 |
Articles10
More Articles| RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1. Oncogenesis 4 , e146, (2015) RUNX1/ETO (RE), the t(8;21)-derived leukemic transcription factor associated with acute myeloid leukemia (AML) development, deregulates genes involved in differentiation, self-renewal and proliferatio... | |
| Bone Marrow Cells in Acute Lymphoblastic Leukemia Create a Proinflammatory Microenvironment Influencing Normal Hematopoietic Differentiation Fates. Biomed Res. Int. 2015 , 386165, (2015) B-cell acute lymphoblastic leukemia (B-ALL) is a serious public health problem in the pediatric population worldwide, contributing to 85% of deaths from childhood cancers. Understanding the biology of... | |
| Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance. Oncogenesis 3 , e122, (2014) Chronic myelogenous leukemia (CML) is maintained by a minor population of leukemic stem cells (LSCs) that exhibit innate resistance to tyrosine kinase inhibitors (TKIs) targeting BCR-ABL. Innate resis... |
Synonyms
| Thelin |
| Sodium (4-chloro-3-methyl-1,2-oxazol-5-yl)({2-[(6-methyl-1,3-benzodioxol-5-yl)acetyl]-3-thienyl}sulfonyl)azanide |
| 3-Thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]-, sodium salt (1:1) |
| Sitax |
| Sitaxsentan sodium |
| Sitaxentan sodium [USAN] |
| Sitaxentan sodium |
| Sitaxsentan (sodium) |
